Stephanie Schonewald Recognized as a World Leading IP Strategist

Dr. Stephanie Schonewald has been recognized in the IAM Strategy 300: The World’s Leading IP Strategists 2025. The IAM Strategy 300 is a listing of individuals identified by market sources as industry pioneers who, “are leading the way in developing and implementing strategies that maximize the value of IP portfolios.”

Stephanie counsels biotech and pharmaceutical companies on the strategic development of patent portfolios, patent prosecution, and post-grant patent challenges, with particular experience in cell therapies, microbiome therapeutics, gene therapies, antibodies and other related immunotherapies, vaccines, antisense oligonucleotides and siRNAs, and diagnostic methods for various diseases. She has handled a variety of third-party submissions and protests before the United States Patent and Trademark Office (USPTO), and over 55 inter partes review, post grant review, and covered business method review proceedings before the Patent Trial and Appeal Board (PTAB). In addition, Stephanie also advises clients on the management of their US patent office activity alongside other global patent activity. She has been named a “World Leading Patent Practitioner” by IAM Patent 1000, a “Top IPR Attorney” by Patexia Insights, a “Top 50 Women in PTAB Trials” by the PTAB Bar Association, a “Life Sciences Star” by LMG Life Sciences, and is recognized by the Legal 500 and Best Lawyers.

IAM Strategy 300: The World’s Leading IP Strategists identifies individuals across entities – from service providers and corporations to research institutions and universities – through confidential nominations and an extensive research process involving face-to-face and telephone interviews with senior members of the global IP community. Qualification also requires nomination by at least three people from outside of their own organization.